The FDA on July 9, 2021 approved DARZALEX FASPRO® in combination with Pomalidomide and Dexamethasone for adult patients with Multiple Myeloma, who have received at least one prior line of therapy including Lenalidomide and a Proteasome Inhibitor. DARZALEX FASPRO® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
